Ann: Appendix 4C and Quarterly Update, page-17

"....................That was on 2mg/kg (cohort one) dosage. We are now 10mg/kg............................."

Hi Kpax, just wondering if you have any thoughts or can throw some light on the fact that in the canine trial, after years of testing and searching for the right dose they settled on 25mg/Kg of body weight. This dose presumably offered the best balance between positive results and minimal (if any) side affects.

Whereas with the human MND trial, as you say, the Cohort 4 group were only given 10mg/Kg. This is less than half of what the dogs are on. So I was wondering if this was due to body size, i.e. humans usually being much larger than dogs? Or maybe, that they hope/expect the humans in the MND trial to need to be on the drug for much longer and so have reduced the amount of drug to compensate for a longer continuous dose? Or maybe just human metabolism is slower so the drug hangs around longer?, or is it just because of the ailment that they are treating, i.e. cancer vs MND.

Thanks for any light you can throw on this query, it would be much appreciated!